文献速递糖尿病肥胖与代谢综合征

减重手术后糖尿病晚期复发:并非罕见,但并非治疗失败

Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure.
PubMed 文献 · Diabetes Care · 2020-01-23

研究纳入736例接受Roux-en-Y胃旁路术(RYGB)或袖状胃切除术(SG)的2型糖尿病(T2DM)患者,425例(58%)术后第1年获得糖尿病缓解,随访中位8年(范围5-14年),136例(32%)出现晚期复发;复发者长期血糖控制、用药数量、血压和血脂仍较术前显著改善。术前糖尿病用药数量、T2DM病程和SG(相比于RYGB)是晚期复发的独立基线预测因素。

要点

  • 425例术后第1年获得糖尿病缓解者中,136例(32%)出现晚期复发。
  • 复发者长期血糖控制、糖尿病用药数量(包括胰岛素使用)、血压和血脂仍显著改善。
  • 术前用药数量、T2DM病程和SG(相比于RYGB)是晚期复发的独立基线预测因素。

核心结论

  • T2DM晚期复发是真实存在的现象(本队列中占三分之一),但不应被视为治疗失败,因为减重手术后疾病轨迹及其相关心血管代谢危险因素获得有利改变。
  • 更早的手术干预、RYGB(相比于SG)和更多体重下降(更少的晚期体重反弹)与长期糖尿病复发较少相关。

研究设计与样本

  • 在学术中心评估736例接受RYGB或SG的T2DM患者(2004-2012年)的结局,这些患者有≥5年的血糖随访。
  • 736例患者中425例(58%)在术后第1年获得糖尿病缓解(HbA1c <6.5% [48 mmol/mol]且未用药),这425例患者随访中位8年(范围5-14年)以描述糖尿病晚期复发。

主要发现

  • 136例(32%)患者出现晚期复发,但在长期随访时仍观察到血糖控制、糖尿病用药数量(包括胰岛素使用)、血压和血脂谱的统计学显著改善。
  • 晚期复发的独立基线预测因素为术前糖尿病用药数量、术前T2DM病程和SG(相比于RYGB)。
  • 复发患者在术后第1年体重下降较少,之后体重反弹更多。
  • 构建了预测模型并进行了外部验证。

关键数值与推荐

  • 糖尿病缓解定义为术后第1年HbA1c <6.5% [48 mmol/mol]且患者未用药。
  • 晚期复发见于136/425例(32%)获得缓解的患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To characterize the status of cardiometabolic risk factors after late relapse of type 2 diabetes mellitus (T2DM) and to identify factors predicting relapse after initial diabetes remission following bariatric surgery to construct prediction models for clinical practice. RESEARCH DESIGN AND METHODS: Outcomes of 736 patients with T2DM who underwent Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) at an academic center (2004-2012) and had ≥5 years' glycemic follow-up were assessed. Of 736 patients, 425 (58%) experienced diabetes remission (HbA1c <6.5% [48 mmol/mol] with patients off medications) in the 1st year after surgery. These 425 patients were followed for a median of 8 years (range 5-14) to characterize late relapse of diabetes. RESULTS: In 136 (32%) patients who experienced late relapse, a statistically significant improvement in glycemic control, number of diabetes medications including insulin use, blood pressure, and lipid profile was still observed at long-term. Independent baseline predictors of late relapse were preoperative number of diabetes medications, duration of T2DM before surgery, and SG versus RYGB. Furthermore, patients who relapsed lost less weight during the 1st year after surgery and regained more weight afterward. Prediction models were constructed and externally validated. CONCLUSIONS: While late relapse of T2DM is a real phenomenon (one-third of our cohort), it should not be considered a failure, as the trajectory of the disease and its related cardiometabolic risk factors is changed favorably after bariatric surgery. Earlier surgical intervention, RYGB (compared with SG) and more weight loss (less late weight regain) are associated with less diabetes relapse in the long-term.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Aminian A, Vidal J, Salminen P, et al. Late Relapse of Diabetes After Bariatric Surgery: Not Rare, but Not a Failure. Diabetes Care. 2020. PMID: 31974105. doi:10.2337/dc19-1057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。